G protein-coupled receptors sit in the plasma membrane, the boundary that defines the inside and outside of a living cell. They communicate with nearly every physiological process in our bodies, from the ability to see and smell, to sensing of adrenaline, insulin, nutrients and medicines. Researchers now report using AI to create tiny, computationally designed proteins to activate or block G protein-coupled receptors. The methods used in their study may form a roadmap for future efforts to create new drug candidates for metabolic, inflammatory, and neurological diseases. These approaches would try to target G protein-coupled receptors that have been largely inaccessible to conventional drug discovery.  

Phillip Tai, PhD, received a $1.6 million grant from the National Institute of General Medical Sciences to investigate the basic mechanisms of adeno-associated viral vectors (AAV) using high-resolution DNA sequencing technology. These findings could potentially lead to new vector designs that improve the safety of gene therapy treatments.

BUFFALO, NY — May 21, 2026 — A new research paper was published in Volume 13 of Oncoscience on April 2, 2026, titled “Selective blood–brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide.”

Wiley today releases the Wiley Registry of Mass Spectral Data 2026, the new edition of one of the world’s largest and most trusted mass spectral reference databases for identifying unknown chemical compounds

Vitamin K has long been linked to bone health, but its precise role remained unclear. A new study shows that vitamin K-dependent γ-carboxylation in osteoblasts regulates bone breakdown through the signaling protein, GAS6. In male mice, blocking this pathway increased bone mass by reducing osteoclast formation, while elevated GAS6 enhanced bone resorption. The findings uncover a previously unknown communication pathway between osteoblasts and osteoclasts, offering insights into osteoporosis and future skeletal therapies.

IBD, which comprises the inflammatory conditions Crohn’s disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated. This mostly is due to a lack in understanding of what exactly causes the increased inflammation, fibrosis, and compromised intestinal barrier that underlie this disease and its manifold symptoms. 

 

A new study, published in Nature Biomedical Engineering and led by Wyss Founding Director Donald Ingber, developed donor-specific microfluidic Organ Chip models of colon that replicate major hallmarks of IBD in vitroin an unprecedented way. Their approach pinpointed new drivers of IBD progression and, for the first time, demonstrated a direct impact of pregnancy hormones on IBD severity in female IBD patient chips and recapitulated the enhanced initiation of cancer formation in IBD tissues.